<DOC>
	<DOCNO>NCT01285362</DOCNO>
	<brief_summary>Over past 30 year , prevalence childhood obesity United States triple 5 % 15 % . Major consequence obesity include insulin resistance , type- 2 diabetes , cardiovascular disease nonalcoholic fatty liver disease ( NAFLD ) . The liver pathology encompass range isolate fatty liver advanced fibrosis , cirrhosis end-stage liver disease . Weight loss , particularly gradual , may lead improvement liver histology . Unfortunately , patient pediatric population willing follow recommendation achieve weight loss . Medical treatment direct specifically liver disease recently investigate approved patient NAFLD . The beneficial effect fish oil attribute high concentration n - 3 fatty acid : eicosapentaenoic acid ( EPA ) docosahexaenoic acid ( DHA ) , major regulator pathways participate decrease production break triglyceride fatty acid liver . We hypothesize child obesity relate NAFLD normalize elevate liver enzyme , plasma lipid level , attenuate insulin resistance supplement n-3 fatty acid . If hypothesis proven true , fish oil could use treat NAFLD prevent deterioration fatty liver end-stage liver disease .</brief_summary>
	<brief_title>Fish Oil Nonalcoholic Fatty Liver Disease ( NAFLD ) Study</brief_title>
	<detailed_description>Scientific Abstract : Over past 30 year , prevalence childhood obesity United States triple 5 % 15 % . Overweight define body mass index ( BMI ) 95 % centile age gender . The recent estimate obesity prevalence base National Health Nutrition Examination Study ( NHANES ) 1999-2000 suggest 15.3 % 15.5 % 6-19 year old child BMI 95 % centile age . Major consequence obesity include insulin resistance , type 2 diabetes mellitus , cardiovascular disease nonalcoholic fatty liver disease ( NAFLD ) . NAFLD represent spectrum condition characterize macrovesicular hepatic steatosis . The liver pathology encompass range isolate fatty liver steatohepatitis , advanced fibrosis , cirrhosis end-stage liver disease . Nonalcoholic steatohepatitis ( NASH ) may progress cirrhosis even child . Weight loss , particularly gradual , may lead improvement liver histology . Unfortunately , patient pediatric population willing follow recommendation achieve weight loss . Pharmacological therapy direct specifically liver disease recently investigate patient NAFLD . Most study uncontrolled pilot study , last one year less produced equivocal result . Thus , currently effective treatment disorder . The beneficial effect fish oil attribute high concentration n - 3 fatty acid : eicosapentaenoic acid ( EPA ) docosahexaenoic acid ( DHA ) . Long-chain polyunsaturated n-3 FA ( LCPUFA ) major regulator molecular pathway alter many area cellular organ function , metabolism gene expression , active reduce inflammation eicasanoid pathway . N-3 LCPUFA well establish negative regulator hepatic lipogenesis . Recently show suppressive effect n-3 LCPUFA lipogenic enzyme mediate reduction mature SREBP-1c protein liver , key transcription factor activate transcription gene involve fatty acid synthesis . It also well establish today n-3 LCPUFA act PPAR-alpha gamma modulators , important triglyceride ( TG ) fatty acid catabolism . N-3 LCPUFA produce dramatic increase size number hepatic peroxisomes increase capacity hepatocyte metabolize fatty acid induce peroxisomal beta-oxidation enzyme , acyl CoA oxidase . We hypothesize child obesity relate NAFLD normalize elevate liver enzyme , plasma lipid level , attenuate insulin resistance supplement n-3 LCPUFA . If hypothesis proven true , fish oil could use treat NAFLD prevent deterioration fatty liver end-stage liver disease . We study 20 patient NAFLD hypertriglyceridemia , age 12y . Excluded study evidence chronic infectious hepatitis , metabolic liver disease , autoimmune chronic cholestatic liver disease , insulin dependent diabetes history alcohol consumption , exposure drug hepatotoxin . Those qualify study age 12 obese individual ( BMI &gt; 95 % age ) , hyperlipidemia , normal fast glucose level . For inclusion elevation serum aminotransferases least 1.5 time upper limit normal minimum 3 month evidence fatty liver abdominal ultrasound liver biopsy . Patients randomize placebo dummy capsule ( control ) n-3 LCPUFA supplement ( Lovaza - GSK Pharmaceuticals , provide free charge ) dose 4gr/day . They follow 3 6 month ; monitor height , weight , BMI , liver enzyme level ( ALT , AST , ALP ) , bilirubin total direct , GGT , plasma phospholipid , plasma lipid , insulin level estimation HOMA-R .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>Body Mass Index ( BMI i.e . wt ( Kg ) /ht ( ) 2 ) 95th % define NHANES table . Elevated liver enzyme ( ALT and/or AST ) least 1.5 time upper limit least 2 examination , ( ALT , upper limit normal value laboratory 41 U/L ; AST , upper limit normal value laboratory 38 U/L ) . Subjects must demonstrate ability swallow capsule . Overt Diabetes Viral autoimmune hepatitis , Wilson 's disease , Alpha1 antitrypsin deficiency , hemochromatosis form chronic liver disease relate NAFLD Exposure drug hepatotoxins less 14 day prior recruitment Alcohol consumption &gt; 20 grams/day Evidence cirrhosis liver biopsy .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Fatty Liver Disease</keyword>
	<keyword>Hepatic Steatosis</keyword>
	<keyword>Docosahexaenoic Acid</keyword>
	<keyword>Eicosapentanoic Acid</keyword>
	<keyword>Omega-3 Fatty Acids</keyword>
	<keyword>Elevated Transaminases</keyword>
	<keyword>Fish oil supplement</keyword>
</DOC>